Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.835
-0.114 (-11.97%)
At close: Mar 6, 2026, 4:00 PM EST
0.840
+0.005 (0.62%)
After-hours: Mar 6, 2026, 7:57 PM EST
Citius Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| Selling, General & Admin | 31.46 | 29.37 | 30.09 | 21.91 | 15.66 | 11.29 | |
| Research & Development | 8.63 | 9.16 | 11.91 | 14.82 | 17.66 | 12.24 | |
| Operating Expenses | 40.09 | 38.53 | 42 | 36.73 | 33.32 | 23.53 | |
| Operating Income | -36.93 | -38.53 | -42 | -36.73 | -33.32 | -23.53 | |
| Interest Expense | -0.42 | -0.27 | - | - | - | -0.01 | |
| Interest & Investment Income | 0.13 | 0.11 | 0.76 | 1.18 | 0.25 | 0.26 | |
| EBT Excluding Unusual Items | -37.22 | -38.68 | -41.24 | -35.55 | -33.06 | -23.28 | |
| Gain (Loss) on Sale of Assets | - | - | 2.39 | 3.59 | - | - | |
| Other Unusual Items | - | - | - | - | - | 0.23 | |
| Pretax Income | -37.8 | -38.68 | -38.85 | -31.97 | -33.06 | -23.05 | |
| Income Tax Expense | 1.06 | 1.06 | 0.58 | 0.58 | 0.58 | - | |
| Earnings From Continuing Operations | -38.85 | -39.74 | -39.43 | -32.54 | -33.64 | -23.05 | |
| Minority Interest in Earnings | 2.97 | 2.31 | 0.29 | - | - | - | |
| Net Income | -35.89 | -37.43 | -39.14 | -32.54 | -33.64 | -23.05 | |
| Preferred Dividends & Other Adjustments | - | - | 1.05 | 1.15 | - | 1.45 | |
| Net Income to Common | -35.89 | -37.43 | -40.19 | -33.69 | -33.64 | -24.51 | |
| Shares Outstanding (Basic) | 15 | 11 | 7 | 6 | 6 | 4 | |
| Shares Outstanding (Diluted) | 15 | 11 | 7 | 6 | 6 | 4 | |
| Shares Change (YoY) | 107.77% | 64.49% | 11.16% | 3.57% | 34.52% | 177.28% | |
| EPS (Basic) | -2.46 | -3.38 | -5.97 | -5.57 | -5.76 | -5.64 | |
| EPS (Diluted) | -2.46 | -3.38 | -5.97 | -5.57 | -5.76 | -5.64 | |
| Free Cash Flow | -34.84 | -26.55 | -28.2 | -29.06 | -28.36 | -24.26 | |
| Free Cash Flow Per Share | -2.39 | -2.40 | -4.19 | -4.80 | -4.85 | -5.58 | |
| EBITDA | -36.36 | -38.52 | -41.99 | -36.73 | -33.31 | -23.53 | |
| D&A For EBITDA | 0.57 | 0 | 0 | 0 | 0 | 0 | |
| EBIT | -36.93 | -38.53 | -42 | -36.73 | -33.32 | -23.53 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.